Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
Hagenacker T, Wurster CD, Günther R, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, Ziegler A, Kuttler J, Koch JC, Schneider I, Wunderlich G, Schloss N, Lehmann HC, Cordts I, Deschauer M, Lingor P, Kamm C, Stolte B, Pietruck L, Totzeck A, Kizina K, Mönninghoff C, von Velsen O, Ose C, Reichmann H, Forsting M, Pechmann A, Kirschner J, Ludolph AC, Hermann A, Kleinschnitz C. Hagenacker T, et al. Among authors: petri s. Lancet Neurol. 2020 Apr;19(4):317-325. doi: 10.1016/S1474-4422(20)30037-5. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199097
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Cudkowicz ME, et al. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Lancet Neurol. 2013. PMID: 24067398 Clinical Trial.
The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross-sectional comparison of established screening tools in a German-Swiss population.
Lulé D, Burkhardt C, Abdulla S, Böhm S, Kollewe K, Uttner I, Abrahams S, Bak TH, Petri S, Weber M, Ludolph AC. Lulé D, et al. Among authors: petri s. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):16-23. doi: 10.3109/21678421.2014.959451. Epub 2014 Oct 8. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 25292386
Clinical features and differential diagnosis of flail arm syndrome.
Hübers A, Hildebrandt V, Petri S, Kollewe K, Hermann A, Storch A, Hanisch F, Zierz S, Rosenbohm A, Ludolph AC, Dorst J. Hübers A, et al. Among authors: petri s. J Neurol. 2016 Feb;263(2):390-395. doi: 10.1007/s00415-015-7993-z. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705123
4-Aminopyridine Induced Activity Rescues Hypoexcitable Motor Neurons from Amyotrophic Lateral Sclerosis Patient-Derived Induced Pluripotent Stem Cells.
Naujock M, Stanslowsky N, Bufler S, Naumann M, Reinhardt P, Sterneckert J, Kefalakes E, Kassebaum C, Bursch F, Lojewski X, Storch A, Frickenhaus M, Boeckers TM, Putz S, Demestre M, Liebau S, Klingenstein M, Ludolph AC, Dengler R, Kim KS, Hermann A, Wegner F, Petri S. Naujock M, et al. Among authors: petri s. Stem Cells. 2016 Jun;34(6):1563-75. doi: 10.1002/stem.2354. Epub 2016 Mar 28. Stem Cells. 2016. PMID: 26946488
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis.
Vercruysse P, Sinniger J, El Oussini H, Scekic-Zahirovic J, Dieterlé S, Dengler R, Meyer T, Zierz S, Kassubek J, Fischer W, Dreyhaupt J, Grehl T, Hermann A, Grosskreutz J, Witting A, Van Den Bosch L, Spreux-Varoquaux O; GERP ALS Study Group; Ludolph AC, Dupuis L. Vercruysse P, et al. Brain. 2016 Apr;139(Pt 4):1106-22. doi: 10.1093/brain/aww004. Epub 2016 Mar 16. Brain. 2016. PMID: 26984187 Clinical Trial.
Age and education-matched cut-off scores for the revised German/Swiss-German version of ECAS.
Loose M, Burkhardt C, Aho-Özhan H, Keller J, Abdulla S, Böhm S, Kollewe K, Uttner I, Abrahams S, Petri S, Weber M, Ludolph AC, Lulé D. Loose M, et al. Among authors: petri s. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):374-6. doi: 10.3109/21678421.2016.1162814. Epub 2016 Mar 30. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 27027323
The concept and diagnostic criteria of primary lateral sclerosis.
Wais V, Rosenbohm A, Petri S, Kollewe K, Hermann A, Storch A, Hanisch F, Zierz S, Nagel G, Kassubek J, Weydt P, Brettschneider J, Weishaupt JH, Ludolph AC, Dorst J. Wais V, et al. Among authors: petri s. Acta Neurol Scand. 2017 Sep;136(3):204-211. doi: 10.1111/ane.12713. Epub 2016 Nov 15. Acta Neurol Scand. 2017. PMID: 27858953
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group. Meininger V, et al. Among authors: petri s. Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28. Lancet Neurol. 2017. PMID: 28139349 Free article. Clinical Trial.
368 results